Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...
Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...
استكشف الفرص مع نوفارتس أدناه.
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax indicates potential to become ...
Cuando se habla de cáncer de próstata, el tiempo no siempre juega en contra. A diferencia de otros tumores, muchos pueden crecer lentamente y sin síntomas durante años. Por eso, el desafío no es ...
Leader mondial dans le domaine de la santé, Novartis propose actuellement l’un des portefeuilles les plus complets du marché. Un portefeuille de médicaments innovants, développés par des personnes ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With ...
Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit and to learn about our generics and radiopharmaceutical products. Please note: Not all treatments are ...
Associate Analyst Regular, Full time General Management India Hyderabad (Office) Junho 25, 2026 ...
A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results